Harvard Bioscience (HBIO) Operating Leases (2019 - 2026)

Harvard Bioscience (HBIO) has 8 years of Operating Leases data on file, last reported at $7.9 million in Q1 2026.

• On a quarterly basis, Operating Leases rose 9.42% year-over-year to $7.9 million in Q1 2026; TTM through Mar 2026 was $7.9 million, a 9.42% increase from a year earlier, with the FY2025 full-year figure at $6.9 million, up 7.85% from the prior year.
• Operating Leases for Q1 2026 stood at $7.9 million, up from $6.9 million in the prior quarter.
• Over the last five years, Operating Leases for HBIO reached as high as $8.8 million in Q2 2025 and fell as low as $4.6 million in Q1 2024.
• Historically, Operating Leases has averaged $6.5 million across 5 years, with a median of $6.5 million in 2023.
• Across the five-year window, Operating Leases sank 41.21% in 2023 and surged 58.66% in 2025, its largest moves.
• Year by year, Operating Leases stood at $5.3 million in 2022, then retreated by 9.24% to $4.8 million in 2023, then jumped by 33.1% to $6.4 million in 2024, then gained by 7.85% to $6.9 million in 2025, then climbed by 14.95% to $7.9 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $7.9 million in Q1 2026, $6.9 million in Q4 2025, and $8.8 million in Q3 2025.